✦ LIBER ✦

Emergence of secondary acute lymphoblastic leukemia of Burkitt type after treatment of rhabdomyosarcoma

✍ Scribed by Miyagi, Takashi ;Nagasaki, Akitoshi ;Nakazato, Tetsuro ;Hyakuna, Nobuyuki ;Takasu, Nobuyuki ;Masuda, Masato

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 60 KB
Volume: 41
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.10414

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Incidence of secondary acute myelogenous

Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia

✍ Susan G. Kreissman; Richard D. Gelber; Harvey J. Cohen; Luis A. Clavell; Pearl L 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 580 KB

Acute leukemia occurring 19 years after

Acute leukemia occurring 19 years after treatment of acute lymphoblastic leukemia

✍ Eduardo E. Reynoso; Armand Keating; Dr. Michael A. Baker 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 241 KB 👁 3 views

A 22-year-old woman presented with acute lymphoblastic leukemia (ALL) during pregnancy. She had been successfully treated for ALL at the age of 3 years and had received maintenance treatment for 11 years. Complete remission of 3 years or more is an important factor for long-term survival and potenti

Emergence of translocation t(9;11)-posit

Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia

✍ Markus Metzler; Pamela L. Strissel; Reiner Strick; Charlotte Niemeyer; Silja Roe 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 1 views

## Abstract Therapy‐related acute myeloid leukemia (t‐AML) characterized by the t(9;11)(p22;q23) translocation is one of the most frequent secondary malignancies. The timing of the initiation of translocation and of development of the malignant t(9;11) clone during chemotherapy is presently unknown

T-cell acute lymphoblastic leukemia foll

T-cell acute lymphoblastic leukemia following therapy of rhabdomyosarcoma

✍ Kaplinsky, Chaim ;Frisch, Amos ;Cohen, Ian J. ;Goshen, Yacov ;Jaber, Lutfi ;Yani 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 420 KB

## Abstract Multiple studies have documented an increased risk of secondary malignancies in patients receiving alkylating agents. Secondary leukemia following chemotherapy accounts for about 20% of all secondary neoplasms; most are acute nonlymphocytic. Secondary acute lymphoblastic leukemia has ra

Chemoimmunotherapy with hyper-CVAD plus

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

✍ Deborah A. Thomas; Stefan Faderl; Susan O'Brien; Carlos Bueso-Ramos; Jorge Corte 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

Treatment of acute lymphoblastic leukemi

Treatment of acute lymphoblastic leukemia in adults

✍ Prof. Tiziano Barbui; Renato Bassan; Teodoro Chisesi; Raffaele Battista; Sergio 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB

Thirty-seven adult patients with acute lymphoblastic leukemia were treated with a protocol called HEAV'D including Adriamycin, Vincristine, L-Asparaginase, Cyclophosphamide and Dexamethasone. The complete remission rate was 70 per cent. The median duration of remission was more than 30 months. Patie